Agoracom: Small Cap Investment - Zenith Epigenetics

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Back To Forum List View

AACR April 24-29, 2020 for some Zenith Clinical Trial Results?

BearDownAZ

Feb 20, 2020 02:24PM

Re: AACR April 24-29, 2020 for some Zenith Clinical Trial Results?

BearDownAZ

Mar 10, 2020 08:53PM

Re: AACR April 24-29, 2020 for some Zenith Clinical Trial Results?

Telepanel

Mar 13, 2020 01:10PM

RVXoldtimer

Rank: President [?]

Points: 3190 [?]

Votes: 23 Score: 3.7 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Exempt Distribution

in response to

Re: AACR April 24-29, 2020 for some Zenith Clinical Trial Results?

Telepanel

posted on Mar 15, 2020 12:34AM

Last Monday, March 9th, 20,000 units of one common share and 1/2 warrant were sold to two parties in Alberta at US$2.72 for US$54,400. The warrants are good for 3 years with an exercise price of US$4.08. (SEDAR)

5 Recommendations

Re: AACR April 24-29, 2020 for some Zenith Clinical Trial Results?

BearDownAZ

Mar 15, 2020 11:54AM

Re: Exempt Distribution

Telepanel

Mar 16, 2020 07:05PM

Re: Exempt Distribution

fouremm

Mar 16, 2020 08:06PM

Re: Exempt Distribution

RVXoldtimer